HDAC3 and neoplasm: Additionally, tucidinostat, by inhibiting HDAC3, in combination with chiglitazar, led to synergistic ferroptotic cell death in LSC-like cell lines and primary CD34+ LSCs, ultimately reducing tumor growth in a PDX model [61].